Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: A Children's Oncology Group Report

British Journal of Haematology

Volumn 167, Issue 3, 2014, Pages 394-401

  Goldman, Stanton ^a   Smith, Lynette ^b   Galardy, Paul ^c   Perkins, Sherrie L ^d   Frazer, John Kimble ^e   Sanger, Warren ^f   Anderson, James R ^b   Gross, Thomas G ^g   Weinstein, Howard ^h   Harrison, Lauren ⁱ   Shiramizu, Bruce ^j   Barth, Matthew ^k   Cairo, Mitchell S ⁱ  

^a Medical City Children's Hospital   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ NEW YORK MEDICAL COLLEGE   (United States)

^j UNIVERSITY OF HAWAII   (United States)

^k ROSWELL PARK CANCER INSTITUTE   (United States)

more..

Author keywords

Burkitt leukaemia; Burkitt lymphoma; Chemotherapy; Children; Rituximab

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; CYTARABINE; DIPHENHYDRAMINE; DOXORUBICIN; ETOPOSIDE; LACTATE DEHYDROGENASE; METHOTREXATE; PARACETAMOL; PREDNISONE; RASBURICASE; RITUXIMAB; VINCRISTINE SULFATE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; VINCRISTINE;

ADOLESCENT; ADULT; ANOREXIA; ARTICLE; BONE MARROW DISEASE; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM LEUKEMIA; CHILD; CLINICAL ARTICLE; CONTINUOUS INFUSION; CYTOGENETICS; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME BLOOD LEVEL; EVENT FREE SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; HYPERURICEMIA; INCIDENCE; LOW DRUG DOSE; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PAIN; PRIORITY JOURNAL; SURVIVAL RATE; SYSTEMIC THERAPY; TUMOR LOCALIZATION; TUMOR LYSIS SYNDROME; TYPHLITIS; BONE MARROW; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHEMICALLY INDUCED; CLINICAL TRIAL; CONSOLIDATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; GENETICS; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; LYMPHOMA, B-CELL; MAINTENANCE CHEMOTHERAPY; MULTICENTER STUDY; ONCOGENE MYC; PATHOLOGY; REMISSION;

ADOLESCENT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; BURKITT LYMPHOMA; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CONSOLIDATION CHEMOTHERAPY; CYCLOPHOSPHAMIDE; CYTARABINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; GENES, MYC; HUMANS; IMMUNOTHERAPY; INFUSIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, B-CELL; MAINTENANCE CHEMOTHERAPY; MALE; METHOTREXATE; PREDNISONE; REMISSION INDUCTION; RITUXIMAB; TYPHLITIS; VINCRISTINE;

EID: 84912027747     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13040     Document Type: Article

References (22)

1. Barnes, J.A., Lacasce, A.S., Feng, Y., Toomey, C.E., Neuberg, D., Michaelson, J.S., Hochberg, E.P. & Abramson, J.S. (2011) Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis. Annals of Oncology, 22, 1859-1864.
2. Barth, M.J., Goldman, S., Smith, L., Perkins, S., Shiramizu, B., Gross, T.G., Harrison, L., Sanger, W., Geyer, M.B., Giulino-Roth, L. & Cairo, M.S. (2013) Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. British Journal of Haematology, 162, 678-683.
3. Cairo, M.S., Gerrard, M., Sposto, R., Auperin, A., Pinkerton, C.R., Michon, J., Weston, C., Perkins, S.L., Raphael, M., McCarthy, K. & Patte, C. (2007) Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood, 109, 2736-2743.
4. Cairo, M., Sposto, R., Gerrard, M., Auperin, A., Goldman, S., Harrison, L., Pinkerton, C.R., Raphael, M., McCarthy, K., Perkins, S. & Patte, C. (2012) Advanced stage, elevated LDH and primary site, but not adolescent age (≥15 years), are associated with an increased risk of failure in children and adolescents with mature B-NHL: results of the FAB/LMB 96 study. Journal of Clinical Oncology, 30, 387-393.
5. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P. & Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 235-242.
6. Corazzelli, G., Frigeri, F., Russo, F., Frairia, C., Arcamone, M., Esposito, G., De Chiara, A., Morelli, E., Capobianco, G., Becchimanzi, C., Volzone, F., Saggese, M., Marcacci, G., De Filippi, R., Vitolo, U. & Pinto, A. (2012) RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and 'unclassifiable' highly aggressive B-cell lymphoma. British Journal of Haematology, 156, 234-244.
7. Dunleavy, K., Pittaluga, S., Shovlin, M., Steinberg, S.M., Cole, D., Grant, C., Widemann, B., Staudt, L.M., Jaffe, E.S., Little, R.F. & Wilson, W.H. (2013) Low-intensity therapy in adults with Burkitt's lymphoma. New England Journal of Medicine, 369, 1915-1925.
8. Foran, J.M., Gupta, R.K., Cunningham, D., Popescu, R.A., Goldstone, A.H., Sweetenham, J.W., Pettengell, R., Johnson, P.W., Bessell, E., Hancock, B., Summers, K., Hughes, J., Rohatiner, A.Z. & Lister, T.A. (2000) A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. British Journal of Haematology, 109, 81-88.
9. Galardy, P., Hochberg, J., Perkins, S., Harrison, L., Goldman, S. & Cairo, M.S. (2013) Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-NHL: a Children's Oncology Group Report. British Journal of Haematology, 163, 365-372.
10. Goldman, S., Smith, L., Anderson, J.R., Perkins, S., Harrison, L., Geyer, M.B., Gross, T.G., Weinstein, H., Bergeron, S., Shiramizu, B., Sanger, W., Barth, M., Zhi, J. & Cairo, M.S. (2013) Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report. Leukemia, 27, 1174-1177.
11. Greenwood, M. (1926) The natural duration of cancer. Reports on Public Health and Medical Subjects, 33, 1-26.
12. Intermesoli, T., Rambaldi, A., Rossi, G., Delaini, F., Romani, C., Pogliani, E.M., Pagani, C., Angelucci, E., Terruzzi, E., Levis, A., Cassibba, V., Mattei, D., Gianfaldoni, G., Scattolin, A.M., Di Bona, E., Oldani, E., Parolini, M., Gokbuget, N. & Bassan, R. (2013) High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program. Haematologica, 98, 1718-1725.
13. Meinhardt, A., Burkhardt, B., Zimmermann, M., Borkhardt, A., Kontny, U., Klingebiel, T., Berthold, F., Janka-Schaub, G., Klein, C., Kabickova, E., Klapper, W., Attarbaschi, A., Schrappe, M. & Reiter, A. (2010) Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. Journal of Clinical Oncology, 28, 3115-3121.
14. Murphy, S.B. (1980) Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults. Seminars in Oncology, 7, 332-339.
15. Patte, C., Auperin, A., Gerrard, M., Michon, J., Pinkerton, R., Sposto, R., Weston, C., Raphael, M., Perkins, S.L., McCarthy, K. & Cairo, M.S. (2007) Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood, 109, 2773-2780.
16. Pfreundschuh, M., Trumper, L., Osterborg, A., Pettengell, R., Trneny, M., Imrie, K., Ma, D., Gill, D., Walewski, J., Zinzani, P.L., Stahel, R., Kvaloy, S., Shpilberg, O., Jaeger, U., Hansen, M., Lehtinen, T., Lopez-Guillermo, A., Corrado, C., Scheliga, A., Milpied, N., Mendila, M., Rashford, M., Kuhnt, E. & Loeffler, M. (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncology, 7, 379-391.
17. Poirel, H.A., Cairo, M.S., Heerema, N.A., Swansbury, J., Auperin, A., Launay, E., Sanger, W.G., Talley, P., Perkins, S.L., Raphael, M., McCarthy, K., Sposto, R., Gerrard, M., Bernheim, A. & Patte, C. (2009) Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study. Leukemia, 23, 323-331.
18. Rubenstein, J.L., Combs, D., Rosenberg, J., Levy, A., McDermott, M., Damon, L., Ignoffo, R., Aldape, K., Shen, A., Lee, D., Grillo-Lopez, A. & Shuman, M.A. (2003) Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood, 101, 466-468.
19. Shaffer, L.G. & Tommerup, N. (eds.) (2005) ISCN 2005: An International System for Human Cytogenetic Nomenclature. S. Karger, Basel, Switzerland.
20. Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J. & Vardiman, J.W. (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IRAC Press, Lyon.
21. Thomas, D.A., Faderl, S., O'Brien, S., Bueso-Ramos, C., Cortes, J., Garcia-Manero, G., Giles, F.J., Verstovsek, S., Wierda, W.G., Pierce, S.A., Shan, J., Brandt, M., Hagemeister, F.B., Keating, M.J., Cabanillas, F. & Kantarjian, H. (2006) Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer, 106, 1569-1580.
22. Woessmann, W., Seidemann, K., Mann, G., Zimmermann, M., Burkhardt, B., Oschlies, I., Ludwig, W.D., Klingebiel, T., Graf, N., Gruhn, B., Juergens, H., Niggli, F., Parwaresch, R., Gadner, H., Riehm, H., Schrappe, M. & Reiter, A. (2005) The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood, 105, 948-958.